Revolutionizing Biomarker Discovery with a High-Throughput
Immunoproteomic Platform
BOSTON, July 30, 2024 /PRNewswire/ -- Sengenics
Corporation LLC is proud to announce the launch of i-Ome Cancer, a
cutting-edge research tool designed to transform cancer biomarker
discovery using just a drop of blood.
i-Ome Cancer marks a significant leap forward in
immunoproteomics, providing a rapid and cost-effective approach to
characterize the immune system's response to cancer. Cancer is
closely associated with protein alterations, which can stimulate
the production of autoantibodies. i-Ome Cancer capitalizes on this
relationship, enabling the direct identification of
disease-associated proteins, offering crucial insights into this
devastating disease and its treatment.
By facilitating high-throughput screening of autoantibodies,
i-Ome Cancer leverages Sengenics's proprietary KREX®
technology to deliver exceptional specificity for robust and
biologically relevant quantitative results, streamlining the
biomarker discovery pipeline.
"Autoantibody profiling with i-Ome Cancer has wide-ranging
applications, from enabling products and services for earlier
diagnoses to guiding the development of cancer vaccines and
therapies," said Dr. Jonathan
Blackburn, Founder and Chief Scientific Officer of
Sengenics. "For example, i-Ome Cancer can reveal how cancer
treatments might induce the immune system to enhance therapeutic
efficacy or potentially cause serious side effects."
The i-Ome Cancer platform comprises a focused library of over
500 expertly curated proteins that are known to be autoantigenic in
cancers, including those frequently mutated in cancer or involved
in key cancer signaling pathways. This latest innovation can screen
twice as many autoantibodies as its predecessor, reinforcing
Sengenics's commitment to advancing cancer research.
Dr. Jessica Da Gama Duarte, a
senior postdoctoral research fellow at the Olivia Newton-John
Cancer Research Institute, stated, "I'm excited about the
expansive cancer content of i-Ome Cancer. It will enable
autoantibody profiling across a larger tumor antigen repertoire,
significantly improving the chances of identifying relevant cancer
biomarkers."
Renowned for its high-quality standards, i-Ome Cancer upholds
Sengenics's reputation for industry-leading reproducibility and
specificity. The platform is now available through service
providers globally, ready to accelerate the future of cancer
precision medicine.
Disclaimer: i-Ome Cancer is for research use only and is not
intended for diagnostic purposes.
About Sengenics
Sengenics Corporation LLC, a functional proteomics company, is
committed to advancing precision medicine by empowering researchers
with biologically relevant and actionable immunoproteomic insights
across a broad spectrum of diseases. At the heart of its mission,
Sengenics offers advanced, high-throughput tools using proprietary
technology to precisely detect autoantibody biomarkers and protein
interactions for basic, translational, and clinical research. Its
robust tools have been leveraged by top pharmaceutical companies
and leading research institutions to enhance disease understanding
and streamline the biomarker pipeline. Sengenics is headquartered
in the U.S. and has a worldwide network of offices, distributors,
and service providers.
Logo -
https://mma.prnewswire.com/media/2344916/Sengenics_margin_wo_tagline_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/sengenics-corporation-unveils-i-ome-cancer-a-breakthrough-in-cancer-precision-medicine-302208775.html